Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
Healio3d
New data support efficacy, safety of povorcitinib for hidradenitis suppurativa
Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...
MPR3d
Povorcitinib Improves Hidradenitis Suppurativa in Two Phase 3 Trials
Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.
INCY Stock Down on Disappointing Skin Disease Study Data
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
Guggenheim downgrades Incyte on povorcitinib’s ‘somewhat underwhelming’ profile
As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...
Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...
Zacks Investment Research on MSN5h
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...
Fierce Biotech3d
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...